Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-31 @ 3:57 AM
Study NCT ID:
NCT07311993
Status:
RECRUITING
Last Update Posted:
2026-01-09
First Post:
2025-11-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Sponsor:
Cellectar Biosciences, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-05
Start Date Type:
ACTUAL
Primary Completion Date:
2028-02
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-07
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-13
First Submit QC Date:
None
Study First Post Date:
2025-12-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-01-08
Last Update Post Date:
2026-01-09
Last Update Post Date Type:
ACTUAL